SiNtx Technologies Inc (SINT)

[boston745]

Revenue is improving but its negligible compared to the companies potential with the various product candidates its sitting on; like laser sintering ZTA implants with Si3N4 to improve their performance. The company is fiscally responsible with low cash burn rate for a company in R&D phase. It has essentially no debt. Its IP is worth hundreds of millions plus, yet you're arguing that the stockprice has no support without contracts? It has no support due to manipulation and naked shorting. Even as contracts have come in its not helped the stockprice. Every bit of positive news has been shorted or naked shorted depending on when the news is released. What is problematic with Sintx is Sonny just sits on all these products without much attempt to commercialize; Atlantas criticism of Sonnys snail pace is accurate but what we dont know is why Sonny just sits on products candidates like that? Guess the new CEO will finally begin commercializing everything Sintx is currently sitting on. That IP has value even if its not generating revenue yet.
Another example of a product candidate that seems to be just sitting on the shelves is masks. There was an attempt to bring masks to market in 2021 but that failed. Why are we now in 2024 and still no new attempt to commercialize with different and better partner? Is this because we've been waiting on 3m divestiture of Solventum to complete? Thats done, now what? The 10k mentions lots of strategic partnerships and thats where things seem to stay for years on end.
Sonny did funds a favor doing with a 200:1 so they can short from 16 or whatever instead of 8 or whatever. Lets see if the price drops 50% once the next offering is announced and then drops another 50% post offering like all of 2023 offerings. What happened in 2023 into Q1 2024 wasnt the result of companies poor performance but pure manipulation which can be seen clearly on the chart; egregious manipulation of the stock actually began in 2022 when the stock began to nosedive wihtout anything inherently negative happening with the company to justify it. Hey TA what to give an updated chart?

Solventum's CEO Bryan Hanson knows all about Si3n4 from his days at Zimmer Biomet. It is curious that Mr Hanson left Zimmer Biomet for Solventum which sells the very products that Si3n4 anti-pathogenic features are perfect for.

We have several partnerships exploring opportunities in face masks, filters, wound care, and coatings.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1269026/000149315224011546/form10-k.htm


https://i.imgur.com/xMRDE8n.jpeg


========================================

A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.

AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.

https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1

Silicon Nitride = Next Gen Hip implant material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

Sintx - Zimmer Connection
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053353

Sintx - Zimmer connection purposefully not disclosed/removed from 2013 IPO paperwork?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174144294

Sintx - Biomet R&D
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053136

Dr. Pezzotti member of Sintx scientific board and his research for Biomet
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174052660

Zimmer Biomet Hires Si3N4 Coatings Expert for its anti-infective dvision - December 2018
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174115529

Zimmer Biomet pays 2.5m certain R&D payment Q2 2017, Dr Bal's investment company loans $2.5m to Sintx.Q3, 2017
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174152867

Sintx - Morgan Ceramics partnership & NP Aerospace Connections
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166246
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166439

Mr Bond, they have a saying in Chicago: 'Once is happenstance. Twice is coincidence. The third time it's enemy action'.

One is an incident, two is a coincidence, three's a pattern, and four is enough for a warrant